Good year for Fresenius and Fresenius Medical Care
This article was originally published in Clinica
In 1997, its first full year of operation, Fresenius Medical Care (FMC) and parent company Fresenius recorded strong turnover and profits. The German group is confident about its prospects for 1998. Not all divisions performed well, however, as sales in FMC's homecare and diagnostics division were down 22%.
You may also be interested in...
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Lilly has launched a similar antibody product, but demand is expected to outpace supply for the foreseeable future.
Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.